TRACON Pharmaceuticals, Inc. (TCON)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.59 Million USD | 0.39% |
| 2022 | -7.62 Million USD | 66.38% |
| 2021 | -22.68 Million USD | 17.83% |
| 2020 | -27.6 Million USD | -149.38% |
| 2019 | -11.06 Million USD | 40.84% |
| 2018 | -18.7 Million USD | 15.06% |
| 2017 | -22.02 Million USD | 22.02% |
| 2016 | -28.24 Million USD | 13.17% |
| 2015 | -32.53 Million USD | -24.8% |
| 2014 | -26.06 Million USD | -15897.58% |
| 2013 | 165 Thousand USD | 106.71% |
| 2012 | -2.45 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -7.89 Million USD | -0.75% |
| 2024 Q2 | -6.27 Million USD | 20.54% |
| 2023 FY | -7.59 Million USD | 0.39% |
| 2023 Q2 | -1.03 Million USD | 82.78% |
| 2023 Q4 | -7.83 Million USD | -10.89% |
| 2023 Q3 | -7.06 Million USD | -582.42% |
| 2023 Q1 | -6.01 Million USD | 21.19% |
| 2022 FY | -7.62 Million USD | 66.38% |
| 2022 Q2 | -12.98 Million USD | 18.58% |
| 2022 Q1 | -15.94 Million USD | 29.71% |
| 2022 Q4 | -7.62 Million USD | 3.98% |
| 2022 Q3 | -7.94 Million USD | 38.81% |
| 2021 Q2 | -22.81 Million USD | 0.66% |
| 2021 Q1 | -22.97 Million USD | 16.78% |
| 2021 FY | -22.68 Million USD | 17.83% |
| 2021 Q4 | -22.68 Million USD | 18.48% |
| 2021 Q3 | -27.82 Million USD | -21.92% |
| 2020 Q2 | -9.94 Million USD | -5.48% |
| 2020 Q1 | -9.42 Million USD | 14.82% |
| 2020 Q4 | -27.6 Million USD | -26.0% |
| 2020 FY | -27.6 Million USD | -149.38% |
| 2020 Q3 | -21.9 Million USD | -120.27% |
| 2019 FY | -11.06 Million USD | 40.84% |
| 2019 Q2 | -19.74 Million USD | -26.76% |
| 2019 Q3 | -13.08 Million USD | 33.74% |
| 2019 Q4 | -11.06 Million USD | 15.38% |
| 2019 Q1 | -15.57 Million USD | 16.75% |
| 2018 FY | -18.7 Million USD | 15.06% |
| 2018 Q4 | -18.7 Million USD | 14.38% |
| 2018 Q3 | -21.85 Million USD | 22.45% |
| 2018 Q2 | -28.17 Million USD | 49.46% |
| 2018 Q1 | -55.74 Million USD | -153.08% |
| 2017 Q2 | -18.79 Million USD | 25.21% |
| 2017 FY | -22.02 Million USD | 22.02% |
| 2017 Q1 | -25.13 Million USD | 11.03% |
| 2017 Q4 | -22.02 Million USD | 13.76% |
| 2017 Q3 | -25.54 Million USD | -35.89% |
| 2016 Q1 | -34.26 Million USD | -5.32% |
| 2016 FY | -28.24 Million USD | 13.17% |
| 2016 Q4 | -28.24 Million USD | -32.45% |
| 2016 Q3 | -21.32 Million USD | 14.2% |
| 2016 Q2 | -24.85 Million USD | 27.46% |
| 2015 Q2 | -54.35 Million USD | 5.47% |
| 2015 FY | -32.53 Million USD | -24.8% |
| 2015 Q3 | -40.23 Million USD | 25.98% |
| 2015 Q4 | -32.53 Million USD | 19.14% |
| 2015 Q1 | -57.49 Million USD | -120.59% |
| 2014 FY | -26.06 Million USD | -15897.58% |
| 2014 Q3 | -29.74 Million USD | -366.41% |
| 2014 Q4 | -26.06 Million USD | 12.36% |
| 2014 Q2 | -6.37 Million USD | 19.34% |
| 2014 Q1 | -7.9 Million USD | -4891.52% |
| 2013 Q1 | 2.45 Million USD | 0.0% |
| 2013 FY | 165 Thousand USD | 106.71% |
| 2013 Q4 | 165 Thousand USD | 0.0% |
| 2012 FY | -2.45 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 518.254% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -99.109% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 705.742% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 123.579% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -708.946% |
| Better Therapeutics, Inc. | -860 Thousand USD | -783.256% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 68.064% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 2412.744% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 266.214% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -30.448% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 337.523% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 339.873% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 251.859% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 105.667% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 4340.022% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 161.563% |
| Molecular Templates, Inc. | 707 Thousand USD | 1174.399% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 1832.49% |
| NexImmune, Inc. | -3.13 Million USD | -142.402% |
| Orgenesis Inc. | 21.78 Million USD | 134.87% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 390.367% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -1525201.205% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -61.252% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -5997.532% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 106.851% |
| Statera Biopharma, Inc. | 14.41 Million USD | 152.69% |
| Trevena, Inc. | 2.25 Million USD | 436.404% |
| Vaxxinity, Inc. | 10.13 Million USD | 174.97% |
| Vaccinex, Inc. | -1.28 Million USD | -489.752% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 2305.28% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 157.376% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 10655.571% |